US Famotidine prices softened in January as renewed export flows and cautious domestic procurement alleviated near-term tightness. Early-month resumption of Chinese shipments and campaign lengths at Indian API complexes boosted availability into the Gulf Coast, while year-end destocking and GPO-led tender activity tempered institutional demand. Elective-procedure normalization provided only a modest lift to hospital injectables, with overall uptake remaining soft amid OTC antacid consumption. The market moved into February with a balanced tone, driven more by competitive CFR offers than by acute supply disruption. Sector dynamics underpinned the softer tone and were echoed in benchmark activity for the Famotidine CFR Houston. Consumer OTC channels for antacid tablets remained steady, while hospital and injectable demand rose modestly. GPO and institutional buying softened after first-quarter tender rounds awarded modest discounts, and formulators largely pursued need-based purchases, contributing to the downshift from January open. Looking ahead, softness is expected in spring, with declines concentrated in February and March before moderating.
